Results from adding adjuvant capecitabine to treatment for breast cancer patients

12:20 EST 13 Dec 2018 | ecancermedicalscience

Dr Miguel Martin speaks to ecancer at SABCS 2018 about the randomised, phase II GEICAM/CIBOMA trial, looking at patients with early-stage triple-negative breast cancer being treated with the chemotherapy agent capecitabine following surgery and standard...

More From BioPortfolio on "Results from adding adjuvant capecitabine to treatment for breast cancer patients"